Article type
Year
Abstract
Background:With the development of medical technology, multiple treatment modalities, including surgery, chemotherapy, targeted therapy, radiotherapy, and immunotherapy, have all led to robust improvements in outcomes for cancers. However, most cancers are still can’t completely be cured, and about a quarter of the world’s population will be directly affected by cancer in 2035.CAR T-cell therapy is one of the most promising methods of tumor immunotherapy in recent years, showing surprising efficacy in many types of malignancies, especially hematopoietic malignancies.Hence, in-depth research on CAR T-cell in the field of cancer is necessary. To the best of our knowledge, there is currently no bibliometric analysis for CAR T-Cell therapy in the field of cancer.
Objectives:We performed a bibliometric study to explore the international collaboration, global hotspots and future prospects regarding chimeric antigen receptors (CAR) T-Cell therapy in the field of cancer research.
Methods:Papers of CAR T-cell research were retrieved from the Web of Science Core Collection. Bibliometric analysis was performed using VOSviewer, CiteSpace and Excel software. Network maps were generated to evaluate the collaborations between different authors, countries, and institutions.
Results:A total number of 1,994 papers related to CAR T-cell research of cancer were included. Since 2009, the number of papers published per year has increased rapidly, especially from 2013 to 2018. Molecular Therapy published the most papers (n=85, 4.26%), followed by Clinical Cancer Research (n=79, 3.96%). A total of 9,792 authors participated in the publication of all papers. June CH (n=54, 2.71%) published the most paper, followed by Dotti G (n=53, 2.66%) and Wang Y (n=52, 2.61%). Sixty-two countries and 2,065 institutions have participated in the publication of all papers. The USA and the University of Pennsylvania published the most papers, respectively. Active cooperation between countries and institutions was observed. The use of CAR T-cell therapy to treat solid tumors other than “leukemia” to improve efficacy and reduce toxicity is the current research hotspot.
Conclusions: CAR T-cell therapy is a promising field of research that will benefit more cancer patients. The USA led in this field, which greatly promoted the development of CAR T-cell research. Chinese institutions and scholars must innovate research methods to improve the quality of published papers. There was a close international cooperation between countries, institutions and authors. Research trends are to improve the immunosuppressive microenvironment of cancer, optimize the structure of CAR T-cells and develop “super CAR T-cell” by using gene-editing technology.
Patient or healthcare consumer involvement: None.
Objectives:We performed a bibliometric study to explore the international collaboration, global hotspots and future prospects regarding chimeric antigen receptors (CAR) T-Cell therapy in the field of cancer research.
Methods:Papers of CAR T-cell research were retrieved from the Web of Science Core Collection. Bibliometric analysis was performed using VOSviewer, CiteSpace and Excel software. Network maps were generated to evaluate the collaborations between different authors, countries, and institutions.
Results:A total number of 1,994 papers related to CAR T-cell research of cancer were included. Since 2009, the number of papers published per year has increased rapidly, especially from 2013 to 2018. Molecular Therapy published the most papers (n=85, 4.26%), followed by Clinical Cancer Research (n=79, 3.96%). A total of 9,792 authors participated in the publication of all papers. June CH (n=54, 2.71%) published the most paper, followed by Dotti G (n=53, 2.66%) and Wang Y (n=52, 2.61%). Sixty-two countries and 2,065 institutions have participated in the publication of all papers. The USA and the University of Pennsylvania published the most papers, respectively. Active cooperation between countries and institutions was observed. The use of CAR T-cell therapy to treat solid tumors other than “leukemia” to improve efficacy and reduce toxicity is the current research hotspot.
Conclusions: CAR T-cell therapy is a promising field of research that will benefit more cancer patients. The USA led in this field, which greatly promoted the development of CAR T-cell research. Chinese institutions and scholars must innovate research methods to improve the quality of published papers. There was a close international cooperation between countries, institutions and authors. Research trends are to improve the immunosuppressive microenvironment of cancer, optimize the structure of CAR T-cells and develop “super CAR T-cell” by using gene-editing technology.
Patient or healthcare consumer involvement: None.